

c.) Remarks

Claim 1 has been amended in order to recite the present invention with the specificity required by statute. Additionally, the Abstract is amended in order to correct an inadvertent typographical error. Accordingly, no new matter has been added.

Claims 1-26 are rejected under 35 U.S.C. §112, first paragraph,

because the specification, while being enabling for popedine [sic] derivatives of formula (I) containing the heterocyclic group where R_1 [sic], R^2 and R^3 contain one o, s [sic] or N, the claims do not reasonably provide enablement for derivatives drawn to the vast range of heterocyclic containing derivatives, particularly, for example, morpholine, pyrimidine or triazo derivatives. The phrase "at least one" is too broad.

This rejection is respectfully traversed. However, solely in order to reduce the issues and expedite the prosecution hereof, claim 1 is amended to reflect the concrete examples of heterocyclic groups exemplified in the specification.


As the Examiner will appreciate, there are numerous examples disclosed wherein any of R^1 , R^2 or R^3 are heterocyclic other than pyridyl; similarly, there are also numerous examples disclosed wherein the heterocyclic group contains two or more hetero atoms. See, e.g., compounds 114, 117, 141-144, 212-213, 217-218, etc.

In view of the above amendments and remarks, Applicants submit that all of the Examiner's concerns are now overcome and the claims are now in allowable condition. Accordingly, reconsideration and allowance of this application is earnestly solicited.

Claims 1-26 remain presented for continued prosecution.

Applicants' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our below listed address.

Respectfully submitted,



Attorney for Applicants
Lawrence S. Perry
Registration No. 31,865

FITZPATRICK, CELLA, HARPER & SCINTO
30 Rockefeller Plaza
New York, New York 10112-3801
Facsimile: (212) 218-2200